NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SUDARSHAN · data 2026-10-31
Sudarshan Pharma Industries Ltd
In plain words
Price: 7.3% below its 52-week high of ₹39.3.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹780 cr |
| Net profit (last 12 months) | ₹29 cr |
| Sales growth, 3 years (yearly) | 15.1% |
| Profit growth, 3 years (yearly) | 49.1% |
At a glance
P/E 31.1, P/B 4.7, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 16.3%, ROCE 28.8%, operating margin 8.0%: how much profit it earns on the money it uses.
Debt/equity 1.84, Profit growth 49.1% and sales growth 15.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 49.1% a year over 3 years.
- High borrowing: debt/equity 1.84.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Sudarshan Pharma Industries Ltd debt-free?
Its latest reported debt-to-equity ratio is 1.84, meaning borrowings are larger than shareholders' equity.
What is Sudarshan Pharma Industries Ltd's P/E ratio?
About 31.1, based on the last 12 months' earnings and a price of ₹36.42 (data 2026-10-31).
What is the 52-week high and low of Sudarshan Pharma Industries Ltd?
The 52-week high is ₹39.3 and the 52-week low is ₹32.1.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
| Sigachi Industries Limited | ₹26.36 | ₹1,009 cr | 39.7 | — | -14.6% | 6.1% | 0.31 | -29.4% |
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Remus Pharmaceuticals Ltd. | ₹843.35 | ₹994 cr | 26.9 | 2.8 | 12.2% | 14.7% | 0.08 | +27.8% |
| Themis Medicare Limited | ₹94.83 | ₹875 cr | 21.9 | — | 0.3% | -2.3% | 0.25 | -24.0% |
| Anuh Pharma Limited | ₹87.31 | ₹873 cr | 15.7 | — | 12.1% | 17% | 0 | -1.1% |
Compare SUDARSHAN with SIGACHI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUDARSHAN in NSE Scanner →